ReviewMolecular and cellular endocrinology2016
Animal models of pituitary neoplasia.
Review in Molecular and cellular endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- The role of stem cells in pituitary tumour formation.Endocrine-related cancer · 2026Review
- INHAND: Non-proliferative and proliferative lesions of fish - Chapter 4. Fish endocrine system.Journal of toxicologic pathology · 2026Article
- Incidence and characterization of spontaneous pituitary neuroendocrine tumors in aged spontaneously hypertensive rats.Scientific reports · 2025Article
- NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations.Endocrine oncology (Bristol, England) · 2024Review
- Intranasal 15d-PGJ2 inhibits the growth of rat lactotroph pituitary neuroendocrine tumors by inducing PPARγ-dependent apoptotic and autophagic cell death.Frontiers in neuroscience · 2023Article
- Clinical Biology of the Pituitary Adenoma.Endocrine reviews · 2022Review
- Sprouting Angiogenesis in Human Pituitary Adenomas.Frontiers in oncology · 2022Article
- The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.Frontiers in endocrinology · 2020Review
- Review
- Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors.Endocrine · 2017Article
- Expression and clinical significance of EGR-1 and PTEN in the pituitary tumors of elderly patients.Oncology letters · 2017Article
- A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control.Endocrine connections · 2017Article
- Article
- The Stem Cell Connection of Pituitary Tumors.Frontiers in endocrinology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Pituitary neoplasias can occur as part of a complex inherited disorder, or more commonly as sporadic (non-familial) disease. Studies of the molecular and genetic mechanisms causing such pituitary tumours have identified dysregulation of >35 genes, with many revealed by studies in mice, rats and zebrafish. Strategies used to generate these animal models have included gene knockout, gene knockin and transgenic over-expression, as well as chemical mutagenesis and drug induction. These animal models provide an important resource for investigation of tissue-specific tumourigenic mechanisms, and evaluations of novel therapies, illustrated by studies into multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome in which ∼ 30% of patients develop pituitary adenomas. This review describes animal models of pituitary neoplasia that have been generated, together with some recent advances in gene editing technologies, and an illustration of the use of the Men1 mouse as a pre clinical model for evaluating novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.